Dermatology specialist Galderma (SWX:GALD) on Wednesday reported new clinical data showing that Nemluvio (nemolizumab) can deliver rapid relief of itch and sleep disturbance as early as 48 hours in patients with moderate-to-severe atopic dermatitis and prurigo nodularis.

Post-hoc analyses of the phase III ARCADIA and OLYMPIA programmes, published in the Journal of the European Academy of Dermatology and Venereology, demonstrated a fast onset of action with benefits increasing through Day 14.

Nemolizumab is the first approved monoclonal antibody to specifically inhibit IL-31 signalling, a neuroimmune cytokine that drives itch in both conditions, and is approved by multiple regulators including in the United States and European Union. Trial data showed significantly higher proportions of patients achieving meaningful reductions in itch and sleep disturbance within two days compared with placebo, with a quarter of atopic dermatitis patients and more than one-third of prurigo nodularis patients responding by Day 14. The findings reinforce the role of IL-31 pathway inhibition in addressing itch, one of the most burdensome symptoms affecting quality of life in these diseases.